ReviewThe EPMA journal2023
Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications-risks and mitigation.
Review in The EPMA journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07301775 (A Randomised Controlled Trial Comparing Efficacy of Single Versus Multiple Intravitreal Anti-VEGF Injections to Prevent Diabetic Retinopathy Progression in Patients Undergoing Cataract Surgery), which is not on this map. Cited by 217 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomised Controlled Trial Comparing Efficacy of Single Versus Multiple Intravitreal Anti-VEGF Injections to Prevent Diabetic Retinopathy Progression in Patients Undergoing Cataract Surgery
Who cites it
217 citing papers in PubMed, 3 syntheses or guidelines pooled it, 363 citations in OpenAlex.
- Association between omega-6 fatty acids and diabetic retinopathy risk: a systematic review and meta-analysis.Nutrition & diabetes · 2026Pooled it
- Clinical practice guidelines for the treatment and management of diabetic macular oedema: a systematic review.Eye (London, England) · 2025Pooled it
- Prevalence of diabetic retinopathy and its associated risk factors among adults in Ethiopia: a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial.Japanese journal of ophthalmology · 2026Trial
- Analysis of 24 pro-inflammatory cytokines in aqueous and serum of 94 patients without diabetes.The British journal of ophthalmology · 2025Trial
- Trial
- Mapping ophthalmic research on glycosylation and glycation: a PRISMA-compliant bibliometric and co‑citation analysis.Future science OA · 2026Article
- Microglial TSPAN4-Dependent Migrasomes Promote Pathological Retinal Neovascularization via Immune-Vascular Crosstalk.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Comparative Analysis of CNN and Transformer Models for Multi-Class Diabetic Retinopathy Grading Using Fundus Images.Diagnostics (Basel, Switzerland) · 2026Article
- Tempol Attenuates Diabetes-induced Transcriptomic Changes in the Rat Retina.Molecular neurobiology · 2026Article
- FOXO6 inhibits SMURF2-mediated ubiquitination and degradation of NR4A1 to promote retinal pigment epithelial cell ferroptosis in diabetic retinopathy.Journal of cell communication and signaling · 2026Article
- Content-based retrieval of fundus images and diabetic retinopathy detection using variants of local texture features.Radiological physics and technology · 2026Article
- Metabolic Dysregulation and Oxidative Stress in Diabetic Retinopathy: Glycogen Metabolism, Mitochondrial Dysfunction, and Antioxidant Defences.Antioxidants (Basel, Switzerland) · 2026Review
- Nyctanthes arbor-tristis attenuates hyperglycemia: an integrated experimental and computational investigation.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Article
- Article
- Ethics of Autonomous AI Clinical Trials: Delphi Study.Journal of medical Internet research · 2026Article
- Association of the Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) Score with Diabetic Retinopathy Severity: A Case-Control Comparison with Non-Diabetic Ophthalmology Patients.Journal of clinical medicine · 2026Article
- Diabetic retinopathy in Greenland and Denmark-Can differences in risk factors explain the lower prevalence in Greenland?Acta ophthalmologica · 2026Article
- Targeting of Nuclear Factor Erythroid 2-Related Factor 2 (NRF2) Signaling Pathway in Age-Related Eye Diseases: Molecular Mechanisms and Opportunities for therapy.Journal of biochemical and molecular toxicology · 2026Review
- Accuracy of portable artificial intelligence-supported fundus camera in the screening of diabetic retinopathy in primary care.Archives of endocrinology and metabolism · 2026Article
157 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proliferative diabetic retinopathy (PDR) the sequel of diabetic retinopathy (DR), a frequent complication of diabetes mellitus (DM), is the leading cause of blindness in the working-age population. The current screening process for the DR risk is not sufficiently effective such that often the disease is undetected until irreversible damage occurs. Diabetes-associated small vessel disease and neuroretinal changes create a vicious cycle resulting in the conversion of DR into PDR with characteristic ocular attributes including excessive mitochondrial and retinal cell damage, chronic inflammation, neovascularisation, and reduced visual field. PDR is considered an independent predictor of other severe diabetic complications such as ischemic stroke. A "domino effect" is highly characteristic for the cascading DM complications in which DR is an early indicator of impaired molecular and visual signaling. Mitochondrial health control is clinically relevant in DR management, and multi-omic tear fluid analysis can be instrumental for DR prognosis and PDR prediction. Altered metabolic pathways and bioenergetics, microvascular deficits and small vessel disease, chronic inflammation, and excessive tissue remodelling are in focus of this article as evidence-based targets for a predictive approach to develop diagnosis and treatment algorithms tailored to the individual for a cost-effective early prevention by implementing the paradigm shift from reactive medicine to predictive, preventive, and personalized medicine (PPPM) in primary and secondary DR care management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.